Skip to contentSkip to filters

We use cookies for analytics.

Topic: mGluR3

ePoster
2 ePosters

In Neuroscience

Amphetamine is used in the therapy of mental disorders and for recreational purposes. However, repeated exposures lead to amphetamine sensitization (AS), which is associated with hyperdopaminergia, cognitive dysfunctions, and aberrant behavior. Notably, mounting evidence indicates that activation of group II metabotropic glutamate receptors (mGluR2 and mGluR3) reverses neuroplasticity associated with AS and prevents both, anxiety and psychosis, in rodent models.We employed a system-oriented approach, murine model of AS, and selective pharmacological tools to explore the specific contribution o

ePoster · Neuroscience

Chronic potentiation of metabotropic glutamate receptor 2 with a nanobody accelerates amyloidogenesis in Alzheimer’s disease

Pierre-Andre Lafon, Mireille Elodie Tsitokana, Ugo Alenda, Clémentine Eva Philibert, Mathieu Oosterlaken, Marta Cimadevila, Jessica Monnic, Salomé Roux, Julie Bessié, Séverine Diem, Franck Vandermoere, Laurent Prézeau, Patrick Chames, Julie Kniazeff, Sylvie Claeysen, Jean-Philippe Pin, Véronique Perrier, Jianfeng Liu, Philippe Rondard · FENS Forum 2024

Immunotherapy of Alzheimer’s disease (AD) is a promising approach to reduce the accumulation of amyloid-beta (Aβ) peptides, a critical event in the onset of the disease. Emerging evidence indicate that metabotropic glutamate receptors (mGluRs) are involved in the progression of AD, representing potential targets for new treatments. Studies have highlighted the potential role of group II mGluRs, mGluR2 and mGluR3, in the modulation of Aβ production, although their respective contribution remains unclear, due to the lack of specific tools to study them. Here, we showed in vitro that enhancing mG

ePoster · Neuroscience